Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine

Stopping treatment for osteoporosis with denosumab (Dmab) leads to a major and rapid loss in bone mineral density (BMD) and a risk of vertebral fracture. Subsequent treatment with bisphosphonate (Bp) does not completely prevent this bone loss. We carried out a prospective pilot study to find out whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroche, Michel, Couture, Guillaume, Degboé, Yannick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339081/
https://www.ncbi.nlm.nih.gov/pubmed/37457878
http://dx.doi.org/10.1002/jbm4.10731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339081/
https://www.ncbi.nlm.nih.gov/pubmed/37457878
http://dx.doi.org/10.1002/jbm4.10731

Ejemplares similares